Status: Recruiting
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacituzumab govitecan * Atezolizumab
Participants needed: 40
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Dana-Farber Cancer InstituteUpdated: May 4, 2026Locations: 7
Eligibility criteria
Pathologically confirmed residual invasive breast cancer, in the breast and/or l... [+26]
Prior therapy with sacituzumab govitecan, irinotecan, or any topoisomerase I-con... [+22]